BrightGene Bio-Medical Technology Statistics

Total Valuation

BrightGene Bio-Medical Technology has a market cap or net worth of CNY 12.37 billion. The enterprise value is 14.01 billion.

Market Cap	12.37B
Enterprise Value	14.01B

Important Dates

The next estimated earnings date is Thursday, April 3, 2025.

Earnings Date	Apr 3, 2025
Ex-Dividend Date	n/a

Share Statistics

BrightGene Bio-Medical Technology has 422.10 million shares outstanding. The number of shares has decreased by -1.19% in one year.

Current Share Class	n/a
Shares Outstanding	422.10M
Shares Change (YoY)	-1.19%
Shares Change (QoQ)	-1.77%
Owned by Insiders (%)	32.24%
Owned by Institutions (%)	28.96%
Float	259.22M

Valuation Ratios

The trailing PE ratio is 65.29 and the forward PE ratio is 58.33.

PE Ratio	65.29
Forward PE	58.33
PS Ratio	9.89
PB Ratio	5.26
P/TBV Ratio	5.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 50.81, with an EV/FCF ratio of -100.85.

EV / Earnings	74.51
EV / Sales	11.29
EV / EBITDA	50.81
EV / EBIT	78.47
EV / FCF	-100.85

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.92.

Current Ratio	1.56
Quick Ratio	0.99
Debt / Equity	0.92
Debt / EBITDA	7.83
Debt / FCF	-15.53
Interest Coverage	3.54

Financial Efficiency

Return on equity (ROE) is 6.00% and return on invested capital (ROIC) is 2.45%.

Return on Equity (ROE)	6.00%
Return on Assets (ROA)	2.27%
Return on Capital (ROIC)	2.45%
Revenue Per Employee	1.07M
Profits Per Employee	162,843
Employee Count	1,155
Asset Turnover	0.25
Inventory Turnover	1.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -1.56% in the last 52 weeks. The beta is 0.35, so BrightGene Bio-Medical Technology's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-1.56%
50-Day Moving Average	31.54
200-Day Moving Average	30.82
Relative Strength Index (RSI)	39.97
Average Volume (20 Days)	7,982,797

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BrightGene Bio-Medical Technology had revenue of CNY 1.24 billion and earned 188.08 million in profits. Earnings per share was 0.45.

Revenue	1.24B
Gross Profit	670.14M
Operating Income	178.61M
Pretax Income	159.16M
Net Income	188.08M
EBITDA	264.60M
EBIT	178.61M
Earnings Per Share (EPS)	0.45

Full Income Statement

Balance Sheet

The company has 505.36 million in cash and 2.16 billion in debt, giving a net cash position of -1.65 billion or -3.92 per share.

Cash & Cash Equivalents	505.36M
Total Debt	2.16B
Net Cash	-1.65B
Net Cash Per Share	-3.92
Equity (Book Value)	2.34B
Book Value Per Share	5.57
Working Capital	497.03M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 215.53 million and capital expenditures -354.50 million, giving a free cash flow of -138.97 million.

Operating Cash Flow	215.53M
Capital Expenditures	-354.50M
Free Cash Flow	-138.97M
FCF Per Share	-0.33

Full Cash Flow Statement

Margins

Gross margin is 53.98%, with operating and profit margins of 14.39% and 15.15%.

Gross Margin	53.98%
Operating Margin	14.39%
Pretax Margin	12.82%
Profit Margin	15.15%
EBITDA Margin	21.31%
EBIT Margin	14.39%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.32%.

Dividend Per Share	0.10
Dividend Yield	0.32%
Dividend Growth (YoY)	-15.79%
Years of Dividend Growth	n/a
Payout Ratio	70.90%
Buyback Yield	1.19%
Shareholder Yield	1.52%
Earnings Yield	1.53%
FCF Yield	-1.12%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BrightGene Bio-Medical Technology has an Altman Z-Score of 3.93.

Altman Z-Score	3.93
Piotroski F-Score	n/a